Woodline Partners’s GSK GSK Stock Holding History

Woodline Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,084,130	Closed	-$36.7M	–	951
2024 Q4	$36.7M	Buy	+1,084,130	New	+$39M	0.25%	125

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners's GSK Position: Q1 2025 in Review

Woodline Partners sold out of GSK (GSK) in Q1 2025, closing a stake of 1,084,130 shares — an estimated $36.7M sold.

Woodline Partners first reported a position in GSK in Q4 2024 and held it in 1 quarter. The position peaked at $36.7M in Q4 2024. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Woodline Partners reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
Woodline Partners sold 1,084,130 GSK shares in Q1 2025, an estimated $36.7M.
Woodline Partners first reported a position in GSK in Q4 2024 and held it in 1 quarter.
Woodline Partners's GSK position peaked at $36.7M in Q4 2024.
857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.